drugset / Trial / NCT04753034
Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
RandomizedParallel-groupDouble-blindTreatment
Summary
This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.
Timeline
- Start
- 2021-01-18
- Primary completion
- 2021-05-03
- Completion
- 2021-05-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TER-101 | Unknown | — | Topical |